About AVIA Biosystems
AVIA Biosystems is a Healthcare company based in Norton (United States) founded in 2012, and was acquired by Unchained Labs in June 2015. Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. AVIA Biosystems has raised $1.1 million across 5 funding rounds from investors including HHS and Unchained Labs. AVIA Biosystems offers products and services including ICD Systems and Model 2304 ICD Systems. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its legal entity is Avia Biosystems, Inc. Its competitors include Somalogic, Nautilus Biotechnology and Amunix; 3 of its 3 listed competitors have raised funding.
Company details
The ICD system makes possible the routine measurement of protein stability under denaturing conditions. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The company has a device developed to facilitate the formulation of biologics in a safe and stable form, the system uses intrinsic or extrinsic fluorescence to monitor the conformational changes associated with protein unfolding (denaturation) and automatically generates complete protein stability curves. In pharmaceutical discovery and development settings, large numbers of constructs or formulations need to be rapidly and easily compared (rank-ordered) for stability. For these applications, automated chemical denaturation provides the most powerful and convenient means to assess protein stability.
- Headquarters Norton, United States
- Stage Acquired
- SectorsHealthcare
- Website aviabiosystems.com
- Social LinkedIn
- Acquired by Unchained Labs (Jun 2015)
- Legal Name Avia Biosystems, Inc.
- Total Equity Funding$1.1M (USD)
in 5 rounds
- Latest Funding Round$207.38K (USD), Grant
Mar 2015
- InvestorsHHS
& 1 more
- Acquired byUnchained Labs
(Jun 2015)
Products & Services of AVIA Biosystems
AVIA Biosystems offers a comprehensive portfolio of products and services, including ICD Systems and Model 2304 ICD Systems.
Measures protein denaturation with minimal samples for biologics testing.
Screens buffers and excipients for protein stability optimization.
Funding Insights of AVIA Biosystems
AVIA Biosystems has successfully raised a total of $1.1M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $207.38 thousand completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.1M
- Total Rounds 5
- Last Round Grant β $207,380
- First Round $1.39M
(Jan 2012)
- Investors Count 1
All 5 funding rounds of AVIA Biosystems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in AVIA Biosystems
AVIA Biosystems has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Unchained Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Multiplex protein stability platform for biologics is developed. | 2015 | unchainedlabs.com | Pleasanton, United States |
Investor details for AVIA Biosystems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AVIA Biosystems
4 dated milestones of AVIA Biosystems across 3 years, from founding to its latest funding, stage changes and deals.
- Founded AVIA Biosystems is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Grant, of $207K.
- Exit Acquired by Unchained Labs.
Competitors of AVIA Biosystems
AVIA Biosystems has 3 listed competitors in our database, 3 of them funded. They include Somalogic, Nautilus Biotechnology and Amunix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. |
Detailed competitors of AVIA Biosystems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as AVIA Biosystems (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AVIA Biosystems
AVIA Biosystems was founded in 2012.
AVIA Biosystems is headquartered in Norton, United States.
AVIA Biosystems is a funded company, having raised a total of $1.1M across 5 funding rounds to date. The company's 1st funding round was a Grant of $1.39M, raised on Jan 2012.
The ICD system makes possible the routine measurement of protein stability under denaturing conditions. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The company has a device developed to facilitate the formulation of biologics in a safe and stable form, the system uses intrinsic or extrinsic fluorescence to monitor the conformational changes associated with protein unfolding (denaturation) and automatically generates complete protein stability curves. In pharmaceutical discovery and development settings, large numbers of constructs or formulations need to be rapidly and easily compared (rank-ordered) for stability. For these applications, automated chemical denaturation provides the most powerful and convenient means to assess protein stability.
AVIA Biosystems's top competitors include Somalogic, Nautilus Biotechnology and Amunix.
AVIA Biosystems offers ICD Systems and Model 2304 ICD Systems.
AVIA Biosystems has 2 investors. Key investors include HHS, and Unchained Labs.
AVIA Biosystems operates through Avia Biosystems, Inc..
Yes. AVIA Biosystems was acquired by Unchained Labs in June 2015.
